Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Masanori Miyazaki"'
Autor:
Machiko Kai, Hayato Hikita, Maesaka Kazuki, Yuki Tahata, Kazuma Shinkai, Akira Doi, Kazuyoshi Ohkawa, Masanori Miyazaki, Hisashi Ishida, Kengo Matsumoto, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Naruyasu Kakita, Naoki Morishita, Naoki Hiramatsu, Takeo Usui, Kazuho Imanaka, Yoshinori Doi, Mitsuru Sakakibara, Yuichi Yoshida, Tsugiko Oze, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 19, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/e034304cabb647119278676fe7668d4a
Autor:
Shiro Hayashi, Mamoru Takenaka, Hirofumi Kogure, Takayuki Yakushijin, Yousuke Nakai, Kenji Ikezawa, Shinjiro Yamaguchi, Toshio Fujisawa, Yuzuru Tamaru, Iruru Maetani, Hirotsugu Maruyama, Satoshi Asai, Tadayuki Takagi, Koji Nagaike, Yasuki Hori, Tetsuya Sumiyoshi, Hidetaka Tsumura, Hisashi Doyama, Toshiyuki Yoshio, Kazuo Hara, Seiichiro Abe, Ichiro Oda, Motohiko Kato, Hiroko Nebiki, Tatsuya Mikami, Masanori Miyazaki, Kazuhiro Matsunaga, Makoto Hosono, Tsutomu Nishida, REX‐GI Study Group
Publikováno v:
DEN Open, Vol 3, Iss 1, Pp n/a-n/a (2023)
Abstract Objectives We surveyed and reported low protective equipment usage and insufficient knowledge among endoscopy‐fluoroscopy departments in Japan in 2020. Two years later, we conducted a follow‐up survey of doctors, nurses, and technologist
Externí odkaz:
https://doaj.org/article/eed24937f59b4761a9c388ad6eb715d4
Autor:
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Akira Doi, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Masanori Miyazaki, Takayuki Yakushijin, Yasutoshi Nozaki, Kengo Matsumoto, Satoshi Tanaka, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Yukinori Yamada, Naoki Morishita, Takeo Usui, Naoki Hiramatsu, Yoshinori Doi, Mitsuru Sakakibara, Kazuho Imanaka, Yuichi Yoshida, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281459 (2023)
AimAlterations in microbial composition of gut microbiota due to antibiotics (ATB) may lead to resistance to immune checkpoint inhibitors (ICIs). This study aimed to assess the impact of ATB use on therapeutic response in patients with hepatocellular
Externí odkaz:
https://doaj.org/article/987d41df248543efad54835c0e7f84eb
Autor:
Yoshihiro Kamada, Maaya Akita, Yuri Takeda, Shin Yamada, Hideki Fujii, Yoshiyuki Sawai, Yoshinori Doi, Hitomi Asazawa, Kotarosumitomo Nakayama, Kayo Mizutani, Hironobu Fujii, Takayuki Yakushijin, Masanori Miyazaki, Hisao Ezaki, Naoki Hiramatsu, Yuichi Yoshida, Shinichi Kiso, Yasuharu Imai, Norifumi Kawada, Tetsuo Takehara, Eiji Miyoshi
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66328 (2013)
Nonalcoholic fatty liver disease (NAFLD) is a growing medical problem around the world. NAFLD patients with nonalcoholic steatohepatitis (NASH) can develop cirrhosis and hepatocellular carcinoma. The ability to distinguish NASH from simple steatosis
Externí odkaz:
https://doaj.org/article/94493805052345049b4451e8919f156c
Autor:
Yuki, Tahata, Ryotaro, Sakamori, Kazuki, Maesaka, Akira, Doi, Ryoko, Yamada, Takahiro, Kodama, Hayato, Hikita, Masanori, Miyazaki, Yasutoshi, Nozaki, Akira, Kaneko, Masahide, Oshita, Satoshi, Tanaka, Kazuho, Imanaka, Naoki, Hiramatsu, Naoki, Morishita, Kazuyoshi, Ohkawa, Takayuki, Yakushijin, Mitsuru, Sakakibara, Sadaharu, Iio, Yoshinori, Doi, Tomohide, Tatsumi, And, Tetsuo, Takehara
Publikováno v:
Hepatology Research. 53:301-311
To determine the impact of direct-acting antiviral (DAA) therapy on the long-term prognosis of decompensated cirrhotic patients.Thirty-seven patients with hepatitis C virus (HCV)-induced decompensated cirrhosis treated with sofosbuvir and velpatasvir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0903f97a13d8ab35b356777bb0340be6
https://doi.org/10.1111/hepr.13868
https://doi.org/10.1111/hepr.13868
Autor:
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yasutoshi Nozaki, Masahide Oshita, Naoki Hiramatsu, Masanori Miyazaki, Eiji Mita, Keiji Yamamoto, Kazuyoshi Ohkawa, Akira Kaneko, Toshifumi Ito, Yoshinori Doi, Takayuki Yakushijin, Taizo Hijioka, Hiroyuki Fukui, Kazuho Imanaka, Yuichi Yoshida, Yukinori Yamada, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Hepatology Research. 52:824-832
Hepatocellular carcinoma (HCC) after sustained virologic response (SVR) has been observed even in hepatitis C virus (HCV) patients without advanced liver fibrosis. Identifying predictors for HCC incidence in patients without advanced liver fibrosis w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e03c3a78bacc996180558e62adbeff77
https://doi.org/10.1111/hepr.13806
https://doi.org/10.1111/hepr.13806
Autor:
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara
Publikováno v:
Hepatology. 77:77-91
Immunotherapy has become the standard-of-care treatment for hepatocellular carcinoma (HCC), but its efficacy remains limited. To identify immunotherapy-susceptible HCC, we profiled the molecular abnormalities and tumor immune microenvironment (TIME)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d234b3344152904598e20d8ee64eeda
https://doi.org/10.1002/hep.32573
https://doi.org/10.1002/hep.32573
Autor:
Hiroki Abe, Masanori Miyazaki, Naofumi Nakazato, Hirotatsu Kishimoto, Atsunori Kamegawa, Hajime Yamamoto, Shuji Ebisu
Publikováno v:
Proceedings of the 29th International Conference on Low Temperature Physics (LT29).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::631bcaf6fcb1de621489f558448b5f87
https://doi.org/10.7566/jpscp.38.011115
https://doi.org/10.7566/jpscp.38.011115
Autor:
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Eiji Mita, Toshifumi Ito, Hideki Hagiwara, Takayuki Yakushijin, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Hepatology Research. 52:298-307
Atezolizumab plus bevacizumab was approved for hepatocellular carcinoma (HCC) patients in 2020, but treatment outcomes of atezolizumab plus bevacizumab in real-world settings remain unclear. Hyperprogressive disease (HPD), an acceleration of tumor gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8394a30f7224b8de0f4d4148e236cce
https://doi.org/10.1111/hepr.13741
https://doi.org/10.1111/hepr.13741
Autor:
Takayuki Matsumae, Takahiro Kodama, Yuta Myojin, Kazuki Maesaka, Ryotaro Sakamori, Ayako Takuwa, Keiko Oku, Daisuke Motooka, Yoshiyuki Sawai, Masahide Oshita, Tasuku Nakabori, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanaka, Eiji Mita, Seiichi Tawara, Takayuki Yakushijin, Yasutoshi Nozaki, Hideki Hagiwara, Yuki Tahata, Ryoko Yamada, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Cancers; Volume 14; Issue 14; Pages: 3367
Combination immunotherapy with anti-programmed cell death1-ligand1 (PD-L1) and anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for patients with unresectable HCC (u-HCC). However, limited patients obtain cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6785ba15dd876a9c4a04c97e2e6ef6
https://pubmed.ncbi.nlm.nih.gov/35884434
https://pubmed.ncbi.nlm.nih.gov/35884434